SKIN Stock Forecast & Price Target

SkinHealth Systems is supported by a resilient, recurring-revenue model in which about 75% of revenue comes from consumables, and its active installed base grew to 36,516 systems, up about 4% y/y, reinforcing long-term monetization potential. Despite 2Q26 revenue declining 8% to $72.1M on a 18% drop in Delivery Systems, adjusted EBITDA rose to $17M and beat guidance materially thanks to gross margin expansion to 71.8%, lower inventory charges, and disciplined expense control. Management’s new U.S. rental program, SkinStylus’ nearly 50% y/y growth, and product catalysts such as a clinically validated booster expected in 4Q26 and continued HydraScalp traction suggest multiple avenues to improve utilization, broaden adoption, and reaccelerate growth.

SkinHealth Systems is under pressure because its revenue and profitability are not yet translating into durable free cash flow, with FY26 revenue guidance lowered, FY26 EBITDA only modeled at about $45M at the high end of guidance, and 3Q26 revenue and adjusted EBITDA guidance both below Street expectations. Despite a roughly $206M cash balance versus a ~$91M market cap, the business still faces a $103MM October 2026 convert and a larger $250MM November 2028 maturity, while capital constraints, weaker device demand, and pressured consumables utilization limit confidence in a sustained recovery. Execution risk around Syndeo, deteriorating provider relationships and brand equity, a 18% y/y decline in Delivery Systems, only 97 net additions from 770 placements, plus litigation, patent, and SEC investigation overhangs, all point to a fragile fundamental setup.